Lessons From the Comparison of Two Randomized Clinical Trials Using Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer
Lessons From the Comparison of Two Randomized Clinical Trials Using Gemcitabine and Cisplatin for Advanced BTC
J Furuse, T Okusaka, J Bridgewater, M Taketsuna, H Wasan, M Koshiji, J Valle
Yes
20110901
2011 Oct 1
Crit Rev Oncol Hematol
Lessons From the Comparison of Two Randomized Clinical Trials Using Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer
Crit Rev Oncol Hematol. 2011 Oct 1;80(1):31-39, J Furuse, T Okusaka, J Bridgewater, M Taketsuna, H Wasan, M Koshiji, J Valle
Abstract
Abstract
There had been no standard chemotherapy established for advanced biliary tract cancer (BTC) until 2009, when the combination of cisplatin and gemcitabine (GC) was adopted as a first line standard chemotherapy option based on the results from two randomized studies: ABC-02, a UK investigator-initiated trial and the largest randomized phase III study in this tumor type with 410 patients; and BT22, a Japanese, industry-sponsored, randomized phase II study with 83 patients. In this review, investigators...
